NSCLC

Roche's Cobas EGFR v2 mutation test will be able to identify advanced NSCLC patients with EGFR mutations who are likely to benefit from the next-generation treatment.

The test was approved for use with Iressa to determine those patients who would benefit by being treated with the drug. 

Health Net's coverage of Biodesix's proteomic test for non-small cell lung cancer follows similar decisions last month by Aetna and Cigna.

Guardant's test will be used to detect mutations associated with acquired resistance to EGFR-inhibiting therapies and to guide further treatment strategies in a study of 600 patients.

The $11 million is in addition to $27 million that the company raised previously in a Series E financing, bringing the total proceeds to $38 million.

The company plans to move away from a centralized lab model to develop kits that can be used by any laboratory to perform its assays, focusing first on developing RUO kits and then clinical assay for lung cancer and more.

The anti-PD-L1 drug significantly extended survival in NSCLC patients with high PD-L1 expression compared to docetaxel, while alectinib shrank tumors for those with ALK-positive tumors and brain metastases.

The firm saw its revenues more than quadruple year over year to $150,000, mainly due to expansion of its commercial liquid biopsy testing business.

Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.

The algorithm may be able to rationally determine the three-drug strategy with the best chance of overcoming resistance and improving survival in advanced lung cancer patients.

Pages

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.